Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 40

1.

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.

Elsahwi KS, Santin AD.

Obstet Gynecol Int. 2011;2011:128295. doi: 10.1155/2011/128295. Epub 2011 Aug 11.

PMID:
21876697
[PubMed]
Free PMC Article
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
3.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24. Review.

PMID:
15107948
[PubMed - indexed for MEDLINE]
4.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S.

Am J Obstet Gynecol. 2005 Mar;192(3):813-8.

PMID:
15746676
[PubMed - indexed for MEDLINE]
5.

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Järvinen TA, Holli K, Kuukasjärvi T, Isola JJ.

Br J Cancer. 1998 Jun;77(12):2267-73.

PMID:
9649144
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer.

Albanell J, Baselga J.

Drugs Today (Barc). 1999 Dec;35(12):931-46.

PMID:
12973420
[PubMed]
7.

Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.

Rabban JT, Zaloudek CJ.

Pathology. 2007 Feb;39(1):125-33. Review.

PMID:
17365828
[PubMed - indexed for MEDLINE]
8.

Treatment of breast cancer.

Maughan KL, Lutterbie MA, Ham PS.

Am Fam Physician. 2010 Jun 1;81(11):1339-46. Review.

PMID:
20521754
[PubMed - indexed for MEDLINE]
Free Article
9.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
[PubMed - indexed for MEDLINE]
10.

p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L.

Am J Pathol. 1997 Jan;150(1):177-85.

PMID:
9006334
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Early uterine serous carcinoma: clonal origin of extrauterine disease.

Baergen RN, Warren CD, Isacson C, Ellenson LH.

Int J Gynecol Pathol. 2001 Jul;20(3):214-9.

PMID:
11444195
[PubMed - indexed for MEDLINE]
12.

Molecular alterations in uterine serous carcinoma.

Hayes MP, Ellenson LH.

Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012. Review.

PMID:
20109727
[PubMed - indexed for MEDLINE]
13.

Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

Boruta DM 2nd, Gehrig PA, Groben PA, Bae-Jump V, Boggess JF, Fowler WC Jr, Van Le L.

Cancer. 2004 Nov 15;101(10):2214-21.

PMID:
15452833
[PubMed - indexed for MEDLINE]
Free Article
14.
15.

Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.

Giordano G, Gnetti L, Merisio C, Melpignano M.

Maturitas. 2007 Feb 20;56(2):190-7. Epub 2006 Sep 11.

PMID:
16963204
[PubMed - indexed for MEDLINE]
16.

Gynecological malignancies.

Schaebler DL, Schilder RJ, Young RC.

Cancer Chemother Biol Response Modif. 1996;16:564-91. Review.

PMID:
8639401
[PubMed - indexed for MEDLINE]
17.

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.

Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L.

Cancer. 2000 Feb 15;88(4):814-24.

PMID:
10679651
[PubMed - indexed for MEDLINE]
18.
19.

The Challenge of Developing New Therapies for Childhood Cancers.

Balis FM.

Oncologist. 1997;2(1):I-II.

PMID:
10388032
[PubMed - as supplied by publisher]
20.

INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.

[No authors listed]

Drugs R D. 2007;8(3):176-87. Review.

PMID:
17472413
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk